Clinical Trials
27 trialsOCCLURANDOM
Gustave Roussy, Cancer Campus, Grand Paris
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
Mayo Clinic
Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
Stanford University
Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
Eastern Cooperative Oncology Group
Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors
Radio Isotope Therapy of America
Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
University of Southern California
Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT
University of Iowa
Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
National Cancer Institute (NCI)
Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
Pfizer
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
National Cancer Institute (NCI)
PALBONET
Grupo Espanol de Tumores Neuroendocrinos
Capecitabine and Temozolomide for Neuroendocrine Cancers
Columbia University
Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
National Cancer Institute (NCI)
Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery
Federation Francophone de Cancerologie Digestive
Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
National Cancer Institute (NCI)
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
Delcath Systems Inc.
Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors
National Cancer Institute (NCI)
Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors
Memorial Sloan Kettering Cancer Center
Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
National Cancer Institute (NCI)
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
Novartis
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
National Cancer Institute (NCI)
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
National Cancer Institute (NCI)
PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors
National Cancer Institute (NCI)
Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum
National Cancer Institute (NCI)